BIOPHYTIS (EPA:ALBPS) - Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

Transparency directive : regulatory news

28/06/2019 17:42

Press release

  Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

* All resolutions within the competence of the Ordinary General Meeting
  adopted
* Second notice to reconvene the Extraordinary General Meeting to be held in
  the coming weeks

Paris (France), Cambridge (Massachusetts, United States), June 28th - Biophytis
S.A. (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company
focused on the development of therapeutics for age-related diseases, today
announces the approval of all resolutions submitted to shareholders during the
Ordinary General Meeting. The Extraordinary General Meeting could not validly
deliberate owing to lack of quorum.

Biophytis' shareholders met for the combined General Meeting on June 28, 2019.
The shareholders present or represented taking part in the vote owned
collectively 3, 052, 493 shares, reaching a quorum of 22.83% of the share
capital, and 22,67 % of the voting rights.

Results of the Ordinary General Meeting

The shareholders approved by a very large majority all the resolutions within
the competence of the Ordinary General Meeting, in particular those ratifying
the unconsolidated and consolidated accounts for fiscal year 2018 and the
allocation of profit for the fiscal year ended December 31, 2018.

Full results of the votes on the resolutions will be available on the Company's
website as from July 1st, 2019, in the "Investors / Regulated information"
section: www.biophytis.com/en/action/document/

Convening of a new Extraordinary General Meeting with the same agenda in the
coming weeks

In the absence of a sufficient quorum, resolutions within the competence of the
Extraordinary General Meeting could not be put to a vote.

The Board decided accordingly that a new Extraordinary General Meeting will be
held in the coming weeks at the following address: Sorbonne Université, 4
place Jussieu, 75005 Paris, to deliberate on the same agenda.

Shareholders who would have already casted their votes with the postal voting
form or by proxy for the Combined Shareholders' Meeting of June 28, 2019, do
not need to return a new voting form, subject to the continued ownership of
their shares.

Shareholders who attended the Combined General Meeting on June 28, 2019 and who
cannot attend the next Extraordinary General Shareholders' Meeting are also
invited to send their forms and shareholder certificates within the
aforementioned period.

Shareholders who would not have voted by post or proxy as part of the first
convening notice will be invited to send their forms and shareholder
certificates after publication of the new meeting notice.

By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées -
14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or via email:
ct-assemblees@caceis.com

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on the development
of therapeutics that slow the degenerative processes and improve functional
outcomes for patients suffering from age-related diseases. Our therapeutic
approach is aimed at targeting and activating key biological resilience
pathways that can protect against and counteract the effects of the multiple
biological and environmental stresses that lead to age-related diseases. Our
lead drug candidate, Sarconeos (BIO101), is an orally administered small
molecule in development for the treatment of neuromuscular diseases, including
sarcopenia and Duchenne muscular dystrophy (DMD). Our second drug candidate,
Macuneos (BIO201), is an orally administered small molecule in development for
the treatment of retinal diseases, including dry age- related macular
degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris,
France, and has offices in Cambridge, Massachusetts. The Company's ordinary
shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN:
FR0012816825). For more information please visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. For a discussion of the risks and uncertainties that could
cause the Company's actual results, financial condition, performance or
achievements to differ from those contained in the Company's forward looking
statements, please consult the Risk Factors section of the Company's
registration document and other regulatory filings filed with the French
Autorité des Marchés Financiers (AMF), which are available on the AMF website
(www.amf-france.org) and at www.biophytis.com. This press release and the
information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to securities of Biophytis in any
country. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements and estimates, which speak only as
of the date hereof. Other than as required by applicable law, Biophytis
undertakes no obligation to update or revise the information contained in this
press release. This press release has been prepared in both French and English.
In the event of any differences between the two texts, the French language
version shall prevail.

Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
dan.schneiderman@biophytis.com
Tel: +1 (857) 220-9720

U.S. Media Contact
LifeSci Public Relations
Cherilyn Cecchini, M.D.
ccecchini@lifescipublicrelations.com
Tel: +1 (646) 876-5196

Europe Media Contact
Citigate Dewe Rogerson
Antoine Denry
antoine.denry@citigatedewerogerson.com
Tel: +33 (0) 1 53 32 84 78

BIOPHYTIS's latest news

15/04/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories